Inflexion acquires Rosemont Pharmaceuticals

Inflexion will acquire Rosemont Pharmaceuticals, a UK liquid pharmaceuticals business.

Rosemont has a portfolio of over 130 oral liquid medicines, including over 70 licensed products which are sold into the UK, US, Europe and the Middle East.

Howard Taylor, CEO of Rosemont, said: “We’re extremely pleased to be able to announce this exciting new chapter for Rosemont. As a very well established and respected supplier in the industry, we look forward to working with Inflexion and drawing on their relevant experience in our sector to continue to invest in the business and expand our quality product range."

Simon Turner, Managing Partner at Inflexion, added: “We are delighted to be partnering with Rosemont on their journey to become a standalone business. Our experience in helping businesses to become independent combined with our success in growing healthcare businesses make us confident our partnership will be an excellent foundation for further innovation and new product development."